Latest news

Kinesis Pharma participates in Drug Rediscovery project

Kinesis Pharma contributed to the nonclinical and clinical scientific justification of using 6-thioguanine (6-TG) in the treatment of patients with inflammatory bowel diseases (IBD) enabling submission of the registration dossier to the authorities in the Netherlands. Kinesis has been working together with pharmaceutical industry, gastroenterologists and pharmacists of University Medical Centres and private parties aiming to obtain official marketing authorization for this product for the treatment of IBD.

For more information www.jgld.ro/2014/2/2.pdf and www.radio1.nl/reporterradio


Back to news overview

Consultants in drug development

Print this page